We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+55.77%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$212M
AUM Growth
+$130M
Cap. Flow
+$77.6M
Cap. Flow %
36.53%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$97.7M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LENZ
1
LENZ Therapeutics
LENZ
$184M
$124M 58.25%
+2,656,888
New +$97.7M
GLUE icon
2
Monte Rosa Therapeutics
GLUE
$1.86B
$41.9M 19.72%
5,652,922
– –
JBIO
3
Jade Biosciences
JBIO
$1.2B
$13.2M 6.2%
1,525,820
– –
CRSP icon
4
CRISPR Therapeutics
CRSP
$4.68B
$9.65M 4.54%
148,831
-349,727
-70% -$20.1M
SKYE icon
5
Skye Bioscience
SKYE
$21.6M
$7.89M 3.71%
2,007,704
– –
CTNM
6
Contineum Therapeutics
CTNM
$529M
$6.38M 3%
542,628
– –
RPTX
7
DELISTED
Repare Therapeutics
RPTX
$4.66M 2.19%
2,646,657
– –
TPST icon
8
Tempest Therapeutics
TPST
$13.9M
$2.77M 1.31%
269,772
– –
ADVM
9
DELISTED
Adverum Biotechnologies
ADVM
$2.3M 1.08%
506,821
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q3 2025 Portfolio in Review

As of Q3 2025, Versant Venture Management held 9 positions worth $212M, up 159% from $82.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $77.6M of net new capital in Q3 2025, opening 1 new position. Its largest new stake was LENZ Therapeutics: 2,656,888 shares worth $124M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was CRISPR Therapeutics, an estimated $20.1M trimmed.

  • Versant Venture Management's largest Q3 2025 buy was LENZ Therapeutics: 2,656,888 shares worth $124M.
  • Versant Venture Management's biggest Q3 2025 reduction was CRISPR Therapeutics, cutting an estimated $20.1M.
  • Versant Venture Management's ten largest holdings make up 100% of its $212M portfolio in Q3 2025.
  • Versant Venture Management opened 1 new position and closed 0 in Q3 2025.
  • Versant Venture Management's portfolio value rose 159% quarter-over-quarter to $212M.

Based on Versant Venture Management's 13F filing for Q3 2025, filed 10 Nov 2025.